Results 151 to 160 of about 15,283 (290)

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

open access: yesEpilepsia, EarlyView.
Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee   +20 more
wiley   +1 more source

Epileptic drop attacks: More than just atonic seizures

open access: yesEpilepsia Open, EarlyView.
Abstract “Drop attacks” are not officially defined by the International League Against Epilepsy. Seizures are characterized by a sudden loss of control over the trunk and posture, leading to falls and injuries, and resolving within a few seconds. Accurately diagnosing the type of seizure is usually difficult due to limitations in clinical documentation
Tomonori Ono   +3 more
wiley   +1 more source

Biopharmaceutics

open access: yesJournal of Pharmacy and Pharmacology, 2006
openaire   +2 more sources

A smart mattress for detecting and correcting the prone position: A feasibility study toward night‐time SUDEP prevention

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in otherwise healthy patients with epilepsy; about 70% occurs during sleep, and nearly 90% of patients are found prone (face‐down). Following a nocturnal seizure, terminal apnea occurs between 2.5 and 10.8 min postictally (median ~ 5 min), defining a narrow but
Jong Woo Lee   +6 more
wiley   +1 more source

Reply to “Understanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis”

open access: yes
Clinical Pharmacology &Therapeutics, EarlyView.
Joachim Almquist   +6 more
wiley   +1 more source

Impact of vigabatrin on risk of relapse of infantile spasms

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Vigabatrin is an effective treatment for infantile epileptic spasms syndrome (IESS), but relapse remains a clinical challenge. The ideal dose and duration of treatment after response are unknown. We set out to identify treatment‐related predictors of IESS relapse after initial vigabatrin response. Methods We conducted a retrospective
Yaretson I. Carmenate   +5 more
wiley   +1 more source

Physiologically Based Biopharmaceutics Modelling-Best Scientific Practices to Define Drug Product Performance, Latest Regulatory and Industry Perspectives: Workshop Summary Report. [PDF]

open access: yesPharmaceutics
McAllister M   +23 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy